Skip to content
10-Q

Quarterly Report

INHIBRX BIOSCIENCES, INC. INBX

0002007919-26-000027

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 14.67M sh
Shares Diluted Q1 2026 · Mar 31, 2026 15.59M sh
Shares Diluted Q1 2026 · Mar 31, 2025 15.47M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $21K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$38.03M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$35.9M
Long Term Debt Q1 2026 · Mar 31, 2026 $174.99M
Long Term Debt Q1 2026 · Dec 31, 2025 $100.56M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $161.66M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $124.22M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$21.04M
Stockholders Equity Q1 2026 · Dec 31, 2025 $7.99M
Stockholders Equity Q1 2026 · Mar 31, 2025 $94.44M
Stockholders Equity Q1 2026 · Dec 31, 2024 $133.58M
Current Liabilities Q1 2026 · Mar 31, 2026 $26.51M
Current Liabilities Q1 2026 · Dec 31, 2025 $33.8M
Total Liabilities Q1 2026 · Mar 31, 2026 $205M
Total Liabilities Q1 2026 · Dec 31, 2025 $138.49M
Current Assets Q1 2026 · Mar 31, 2026 $171.34M
Current Assets Q1 2026 · Dec 31, 2025 $132.83M
Total Assets Q1 2026 · Mar 31, 2026 $183.97M
Total Assets Q1 2026 · Dec 31, 2025 $146.48M
Eps Diluted Q1 2026 · Mar 31, 2026 −$2.15
Eps Diluted Q1 2026 · Mar 31, 2025 −$2.80
Eps Basic Q1 2026 · Mar 31, 2026 −$2.15
Eps Basic Q1 2026 · Mar 31, 2025 −$2.80
Sga Expense Q1 2026 · Mar 31, 2026 $5.71M
Sga Expense Q1 2026 · Mar 31, 2025 $6.02M
Rd Expense Q1 2026 · Mar 31, 2026 $25.22M
Rd Expense Q1 2026 · Mar 31, 2025 $36.88M
Net Income Q1 2026 · Mar 31, 2026 −$33.44M
Net Income Q1 2026 · Mar 31, 2025 −$43.31M
Operating Income Q1 2026 · Mar 31, 2026 −$30.93M
Operating Income Q1 2026 · Mar 31, 2025 −$42.9M